{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:56:00Z","timestamp":1791532560285,"version":"4.3.4"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.pnpbp.2005.11.005","type":"journal-article","created":{"date-parts":[[2006,1,24]],"date-time":"2006-01-24T04:36:32Z","timestamp":1138077392000},"page":"362-373","source":"Crossref","is-referenced-by-count":120,"title":["Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder"],"prefix":"10.1016","volume":"30","author":[{"given":"Mostafa","family":"El Mansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2005.11.005_bib1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.biopsych.2004.11.042","article-title":"Deep brain stimulation for refractory obsessive-compulsive disorder","volume":"57","author":"Abelson","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib2","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1016\/S0021-9258(19)39437-2","article-title":"Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine1A receptor gene","volume":"265","author":"Albert","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib3","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00213-004-1847-1","article-title":"Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study","volume":"174","author":"Arnold","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1176\/ajp.154.9.1293","article-title":"Addition of desipramine to serotonin reuptake inhibitors in treatment-resistent obsessive-compulsive disorder","volume":"154","author":"Barr","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0193-953X(18)30215-6","article-title":"Neuroimaging studies of obsessive compulsive disorder","volume":"15","author":"Baxter","year":"1992","journal-title":"Psychiatry Clin North Am"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/archpsyc.1987.01800150017003","article-title":"Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls","volume":"44","author":"Baxter","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0014-2999(95)00080-5","article-title":"The pre- and postjunctional activity of CP-122,288, a conformationally restricted analogue of sumatriptan","volume":"276","author":"Beattie","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/archpsyc.1989.01810010025004","article-title":"Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action","volume":"46","author":"Benkelfat","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/archpsyc.1990.01810210048007","article-title":"Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine","volume":"47","author":"Benkelfat","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00004714-200204000-00007","article-title":"Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study","volume":"22","author":"Bergeron","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0006-3223(98)00154-1","article-title":"Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder","volume":"15","author":"Bergqvist","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s002130050923","article-title":"Effect of atypical antipsychotic drugs on 5-HT2 receptors in the rat orbitofrontal cortex: an in vivo electrophysiological study","volume":"143","author":"Bergqvist","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib13","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1523\/JNEUROSCI.03-06-01270.1983","article-title":"Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat","volume":"3","author":"Blier","year":"1983","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0306-4522(85)90107-1","article-title":"Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors","volume":"16","author":"Blier","year":"1985","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib15","first-page":"987","article-title":"Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system","volume":"237","author":"Blier","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/BF00168834","article-title":"Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain","volume":"337","author":"Blier","year":"1988","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0014-2999(92)90394-J","article-title":"Effect of repeated electroconvulsive shocks on serotonergic neurons","volume":"211","author":"Blier","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1476-5381.1994.tb17015.x","article-title":"Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs","volume":"113","author":"Blier","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib17","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1097\/00004714-199006001-00004","article-title":"Differential effect of gepirone on presynaptic and postsynaptic serotonin receptors: single-cell recording studies","volume":"10","author":"Blier","year":"1990","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0165-6147(94)90315-8","article-title":"Current advances and trends in the treatment of depression","volume":"15","author":"Blier","year":"1994","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib19","first-page":"7","article-title":"Differential properties of pre- and postsynaptic 5-hydroxytryptamine1A receptors in the dorsal raphe and hippocampus: I. Effect of spiperone","volume":"265","author":"Blier","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/00004583-200108000-00011","article-title":"Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD","volume":"40","author":"Bolton","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib23","first-page":"645","article-title":"Acute and chronic effects of citalopram on postsynaptic 5-hydroxytryptamine(1A) receptor-mediated feedback: a microdialysis study in the amygdala","volume":"761","author":"Bosker","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0925-4927(98)00041-9","article-title":"FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder","volume":"84","author":"Brody","year":"1998","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1017\/S1461145703003869","article-title":"A family-based association study of the 5-HT1Dbeta receptor gene in obsessive-compulsive disorder","volume":"7","author":"Camarena","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF00500007","article-title":"Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain","volume":"333","author":"Chaput","year":"1986","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib27","first-page":"219","article-title":"Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat","volume":"5","author":"Chaput","year":"1991","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0031-9384(03)00047-7","article-title":"Compulsive behavior in the 5-HT2C receptor knockout mouse","volume":"78","author":"Chou-Green","year":"2003","journal-title":"Physiol Behav"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00213-003-1396-z","article-title":"Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder","volume":"167","author":"Coric","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00001756-200403220-00025","article-title":"Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder","volume":"15","author":"Delorme","year":"2004","journal-title":"Neuroreport"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib31","first-page":"230","article-title":"Electroconvulsive shock treatments enhance responsiveness of forebrain neurons to serotonin","volume":"228","author":"de Montigny","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4088\/JCP.v65n0106","article-title":"A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder","volume":"65","author":"Denys","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib34","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1476-5381.1996.tb15454.x","article-title":"Functional characterization of 5-HT1D autoreceptors on the modulation of 5-HT release in guinea-pig mesencephalic raphe, hippocampus and frontal cortex","volume":"118","author":"El Mansari","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib35","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0028-3908(97)00035-X","article-title":"In vivo electrophysiological characterization of 5-HT receptors in the guinea pig head of caudate nucleus and OFC","volume":"36","author":"El Mansari","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib36","first-page":"268","article-title":"Responsiveness of postsynaptic 5-HT1A and 5-HT2 receptors in rat OFC following long-term serotonin reuptake inhibition","volume":"30","author":"El Mansari","year":"2005","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0893-133X(95)00045-F","article-title":"Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder","volume":"13","author":"El Mansari","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib37","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/S0140-6736(05)78746-8","article-title":"5-HT2A promoter polymorphism \u22121438G\/A, anorexia nervosa, and obsessive-compulsive disorder","volume":"351","author":"Enoch","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euroneuro.2004.04.004","article-title":"Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"15","author":"Erzegovesi","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00004850-199206001-00012","article-title":"Serotonin reuptake inhibitors are treatment of choice in obsessive compulsive disorder","volume":"7","author":"Fineberg","year":"1992","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib40","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/0278-5846(85)90025-9","article-title":"Fluoxetine in the treatment of obsessive compulsive disorder","volume":"9","author":"Fontaine","year":"1985","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0924-977X(00)00071-7","article-title":"Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways","volume":"10","author":"Frisch","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib42","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0022-3565(24)38843-3","article-title":"Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study","volume":"296","author":"Gobbi","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archpsyc.1989.01810010038006","article-title":"Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib44","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archpsyc.1990.01810180077011","article-title":"Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine","volume":"47","author":"Goodman","year":"1990","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 5","key":"10.1016\/j.pnpbp.2005.11.005_bib45","first-page":"32","article-title":"Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions","volume":"58","author":"Goodman","year":"1997","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 4","key":"10.1016\/j.pnpbp.2005.11.005_bib46","first-page":"33","article-title":"SSRIs and SNRIs: broad spectrum of efficacy beyond major depression","volume":"60","author":"Gorman","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib47","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s002130050787","article-title":"Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients","volume":"140","author":"Greenberg","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004850-199506000-00001","article-title":"A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder","volume":"10","author":"Greist","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib49","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1476-5381.1995.tb15084.x","article-title":"The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation","volume":"116","author":"Gupta","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib50","doi-asserted-by":"crossref","first-page":"10150","DOI":"10.1523\/JNEUROSCI.18-23-10150.1998","article-title":"Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors","volume":"18","author":"Haddjeri","year":"1998","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib51","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0893-133X(99)00138-4","article-title":"Increased tonic activation of rat forebrain 5-HT1A receptors by lithium addition to antidepressant treatments","volume":"22","author":"Haddjeri","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004714-199604000-00011","article-title":"Serotonin, psilocybin, and body dysmorphic disorder: a case report","volume":"16","author":"Hanes","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib53","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1176\/ajp.148.9.1243","article-title":"Effects of fluoxetine on regional cerebral blood flow in obsessive-compulsive patients","volume":"148","author":"Hoehn-Saric","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib54","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/0006-3223(85)90176-3","article-title":"Obsessive-compulsive disorder and serotonin: is there a connection?","volume":"20","author":"Insel","year":"1985","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib55","first-page":"487","article-title":"Obsessive-compulsive disorder: efficacy of specific treatments as assessed by controlled trials","volume":"29","author":"Jenike","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib56","first-page":"S205","article-title":"Riluzole augmentation in the treatment of major depressive disorder","volume":"29","author":"Kendell","year":"2004","journal-title":"Am Coll Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib57","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0924-977X(01)00082-7","article-title":"Sumatriptan, 5-HT1D receptors and obsessive-compulsive disorder","volume":"11","author":"Koran","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib58","doi-asserted-by":"crossref","first-page":"1239b","DOI":"10.1176\/ajp.144.9.1239b","article-title":"Relief of obsessive compulsive symptoms by LSD and psilocin","volume":"144","author":"Leonard","year":"1987","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib59","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/archpsyc.1991.01810340054007","article-title":"A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder","volume":"48","author":"Leonard","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00176767","article-title":"Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine","volume":"352","author":"Le Poul","year":"1995","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib61","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0028-3908(99)00088-X","article-title":"Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine","volume":"39","author":"Le Poul","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib62","article-title":"Effects of treatment with LY354740, lorazepam, or placebo in patients with a primary diagnosis of generalized anxiety disorder","volume":"74","author":"Levine","year":"2003","journal-title":"Am Coll Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib63","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF02244438","article-title":"Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder","volume":"105","author":"Lesch","year":"1991","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib64","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0022-3565(24)36965-4","article-title":"A desensitization of hypothalamic 5-HT1A receptors by repeated injections of paroxetine: reduction in the levels of G(i) and G(o) proteins and neuroendocrine responses, but not in the density of 5-HT1A receptors","volume":"282","author":"Li","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib65","first-page":"1035","article-title":"Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain G(i) and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist","volume":"279","author":"Li","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib66","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1176\/ajp.150.4.647","article-title":"Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder","volume":"150","author":"McDougle","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib67","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","article-title":"A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder","volume":"57","author":"McDougle","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-2999(01)01469-8","article-title":"LY393558, a 5-hydroxytryptamine reuptake inhibitor and 5-HT(1B\/1D) receptor antagonist: effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat","volume":"432","author":"Mitchell","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib69","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1176\/jnp.1.1.27","article-title":"Neurophysiologic dysfunction in basal ganglia\/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder","volume":"1","author":"Modell","year":"1989","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib70","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00004850-199206001-00003","article-title":"Fluvoxamine in the treatment of obsessive compulsive disorder","volume":"7","author":"Montgomery","year":"1992","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0924-977X(93)90266-O","article-title":"A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group","volume":"3","author":"Montgomery","year":"1993","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib72","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1176\/ajp.154.7.1037b","article-title":"Hallucinogen-induced relief of obsessions and compulsion","volume":"154","author":"Moreno","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib73","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0014-2999(90)90320-6","article-title":"Serotonin autoreceptor subsensitivity and antidepressant activity","volume":"180","author":"Moret","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib74","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.mp.4001059","article-title":"5HT1Dbeta Receptor gene implicated in the pathogenesis of Obsessive-Compulsive Disorder: further evidence from a family-based association study","volume":"7","author":"Mundo","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib75","first-page":"461","article-title":"DRD2, DRD3 and 5HT2A receptor genes polymorphisms in obsessive-compulsive disorder","volume":"1","author":"Nicolini","year":"1996","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib76","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0893-133X(89)90003-1","article-title":"Cerebral glucose metabolic rates in obsessive disorder","volume":"2","author":"Nordahl","year":"1989","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib77","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/sj.mp.4001144","article-title":"A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry","volume":"7","author":"Nordstrom","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib78","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00023210-199707030-00003","article-title":"Obsessive-compulsive disorder. Treatment options","volume":"7","author":"Park","year":"1997","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib79","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s002130050777","article-title":"Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder","volume":"140","author":"Pian","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004714-199202000-00003","article-title":"A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder","volume":"12","author":"Pigott","year":"1992","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib81","first-page":"697","article-title":"Regulation of 5-hydroxytryptamine release from rat midbrain raphe nuclei by 5-hydroxytryptamine1D receptors: effect of tetrodotoxin, G protein inactivation and long-term antidepressant administration","volume":"276","author":"Pineyro","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib82","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejphar.2004.04.029","article-title":"The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig","volume":"493","author":"Pullar","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib83","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0022-3565(24)37930-3","article-title":"Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins","volume":"288","author":"Raap","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib84","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/j.1471-4159.1992.tb11347.x","article-title":"Pharmacological and physicochemical properties of pre-versus postsynaptic 5-hydroxytryptamine1A receptor binding sites in the rat brain: a quantitative autoradiographic study","volume":"58","author":"Radja","year":"1992","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib85","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.1994.03950010062008","article-title":"Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography","volume":"51","author":"Rauch","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib87","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1017\/S1461145701002401","article-title":"Brain anatomy and chemistry may predict treatment response in paediatric obsessive-compulsive disorder","volume":"4","author":"Rosenberg","year":"2001","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib86","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/00004583-200009000-00008","article-title":"Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine","volume":"39","author":"Rosenberg","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib88","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s002109900181","article-title":"In vivo electrophysiological examination of 5-HT2 responses in 5-HT2C receptor mutant mice","volume":"361","author":"Rueter","year":"2000","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib89","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0893-133X(99)00082-2","article-title":"Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder","volume":"21","author":"Saxena","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib90","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1192\/S0007125000297882","article-title":"Neuroanatomical aspects of cognitive-behavioural therapy response in obsessive-compulsive disorder. An evolving perspective on brain and behaviour","volume":"35","author":"Schwartz","year":"1998","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib91","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3565(24)29296-X","article-title":"Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system","volume":"299","author":"Schoepp","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib92","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0278-5846(99)00051-2","article-title":"Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor","volume":"23","author":"Stein","year":"1999","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib93","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/archpsyc.1992.01820090018003","article-title":"Cerebral glucose metabolism in childhood-onset obsessive compulsive disorder. Revisualization during pharmacotherapy","volume":"49","author":"Swedo","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib94","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archpsyc.1994.03950070051010","article-title":"A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder","volume":"51","author":"Tollefson","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib95","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0924-9338(03)00066-X","article-title":"T102C and \u22121438 G\/A polymorphisms of the 5-HT2A receptor gene in Turkish patients with obsessive-compulsive disorder","volume":"18","author":"Tot","year":"2003","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib96","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/BF00260601","article-title":"5-HT1D receptors in guinea-pig and pigeon brain. Radioligand binding and biochemical studies","volume":"340","author":"Waeber","year":"1989","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib97","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/BF00164585","article-title":"Metitepine distinguishes two receptors mediating inhibition of [3H]-5-hydroxytryptamine release in guinea pig hippocampus","volume":"345","author":"Wilkinson","year":"1992","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib98","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0028-3908(93)90101-8","article-title":"Stereoselective actions of the isomers of metitepine at 5-HT1D receptors in the guinea pig brain","volume":"32","author":"Wilkinson","year":"1993","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib99","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.biopsych.2004.11.023","article-title":"An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression","volume":"57","author":"Zarate","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.11.005_bib100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1017\/S1461145702003218","article-title":"Enhancing action of LSD on neuronal responsiveness to serotonin in a brain structure involved in obsessive-compulsive disorder","volume":"6","author":"Zghoul","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl 14","key":"10.1016\/j.pnpbp.2005.11.005_bib101","first-page":"18","article-title":"Serotonin1D hypothesis of obsessive-compulsive disorder: an update","volume":"65","author":"Zohar","year":"2004","journal-title":"J Clin Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584605003490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584605003490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T09:50:29Z","timestamp":1736243429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584605003490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0278584605003490"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2005.11.005","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}